ACUTE MYELOID LEUKEMIA (AML)
Clinical trials for ACUTE MYELOID LEUKEMIA (AML) explained in plain language.
Never miss a new study
Get alerted when new ACUTE MYELOID LEUKEMIA (AML) trials appear
Sign up with your email to follow new studies for ACUTE MYELOID LEUKEMIA (AML), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug tested for Tough-to-Treat blood cancers
Disease control TerminatedThis study tested a new antibody drug called GEN3014 in people with multiple myeloma and other blood cancers that had returned or stopped responding to standard treatments. The main goals were to find a safe dose and see if the drug showed early signs of helping control the cance…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New hope to stop Leukemia's return after transplant
Disease control TerminatedThis study tested whether adding two drugs, venetoclax and azacitidine, as ongoing 'maintenance therapy' could help people with acute myeloid leukemia (AML) live longer after a stem cell transplant. It compared this drug combination to standard supportive care alone. The goal was…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Early trial tests new drug combos for tough blood cancers
Disease control TerminatedThis early-stage study tested two different drug combinations for adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS), two serious blood and bone marrow cancers. The main goal was to find safe doses and see how well the combinations were tolerated…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New hope for tough blood cancers? experimental drug enters human testing
Disease control TerminatedThis study tested a new drug called NMS-03592088 in adults whose acute myeloid leukemia (AML) or chronic myelomonocytic leukemia (CMML) had returned or did not respond to standard treatments. The main goals were to find a safe dose and see if the drug could help control the cance…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE1, PHASE2 • Sponsor: Nerviano Medical Sciences • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New hope for patients out of options: experimental drug enters first human trials
Disease control TerminatedThis early-stage study tested a new drug called voruciclib, both alone and combined with another drug (venetoclax), in adults with advanced blood cancers like leukemia and lymphoma. The main goal was to find safe dosage levels and see if the treatment showed any early signs of he…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE1 • Sponsor: MEI Pharma, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Novartis halts early trial of promising blood cancer drug duo
Disease control TerminatedThis early-stage study aimed to find a safe dose and schedule for a new two-drug combination (VOB560 and MIK665) for patients whose non-Hodgkin lymphoma, acute myeloid leukemia, or multiple myeloma had returned or stopped responding to other treatments. The drugs were designed to…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 23, 2026 15:29 UTC
-
New hope for kids with Tough-to-Treat leukemia
Disease control TerminatedThis study tested a new drug, gilteritinib, combined with standard chemotherapy in children and young adults with a specific, aggressive form of acute myeloid leukemia (AML) that had come back or did not respond to initial treatment. The goal was to find a safe and effective dose…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE1, PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
New 'Living Drug' trial targets Tough-to-Treat blood cancers
Disease control TerminatedThis early-stage trial tested a new type of personalized cell therapy for adults with acute myeloid leukemia (AML) that has come back or hasn't responded to other treatments. Doctors modified patients' own immune cells (T-cells) to target a protein called CD123 found on cancer ce…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE1 • Sponsor: AvenCell Europe GmbH • Aim: Disease control
Last updated Mar 11, 2026 14:54 UTC